REGULATED INFORMATION
PRESS RELEASE
Transparency
notifications
pursuant to Article 14 of the Law of May 2, 2007
Leuven (Belgium)
- June 19, 2018, 22:00h CET - TiGenix NV (Euronext Brussels and
Nasdaq: TIG; "TiGenix") announced today that it received
transparency notifications pursuant to Article 14 of the Belgian
Law of May 2, 2007 regarding the publication of major holdings in
issuers whose securities are admitted to trading on a regulated
market and including various provisions.
Summary of the
notifications
It concerns the following two
notifications:
-
On June 14, 2018, TiGenix received a joint
transparency notification from Takeda Pharmaceutical Company
Limited and Grifols, S.A. following the acquisition of voting
securities or voting rights and the termination of an agreement to
act in concert on June 8, 2018, after which Takeda Pharmaceutical
Company Limited (including through its subsidiary Takeda
Pharmaceuticals International AG) holds 268,309,029 voting rights
in TiGenix (90.62% of the total number of voting rights). As a
result Takeda Pharmaceutical Company Limited crossed the 90%
threshold and Grifols, S.A. downward crossed the lowest threshold
(3%) of the total voting rights of TiGenix.
-
On June 18, 2018, TiGenix received a
transparency notification from Bank of America Corporation,
following the disposal of financial instruments that are treated as
voting securities on June 11, 2018, after which Bank of America
Corporation (through its controlled entities Bank of America
National Association and Merrill Lynch Professional Clearing
Corporation) downward crossed the lowest threshold (3%) of the
total voting rights of TiGenix.
1. Content of the
notification of Takeda Pharmaceutical Company Limited and Grifols,
S.A.
Date of the
notification: June 11, 2018.
Reason of the
notification: acquisition or disposal of voting securities or
voting rights / termination of an agreement to act in concert.
Persons subject
to the notification requirement: Takeda Pharmaceutical Company
Limited (with address at 1-1 Doshomachi 4-Chome, Chuo-ku, Osaka
540-8645, Japan), who is a parent undertaking/controlling person
and who is acting in concert with Grifols S.A. (with address at
Avenida de la Generalitat 152, 08147 Sant Cugat de Vallès,
Barcelona, Spain), who is a parent undertaking/controlling
person.
Date on which the
threshold was crossed: June 8, 2018.
Threshold that
was crossed: 90% (Takeda Pharmaceutical Company Limited); 3%
(Grifols, S.A.).
Denominator:
296,067,856.
Details of the
notification: following the acquisition of voting securities or
voting rights, the number of voting rights was as follows:
-
Takeda Pharmaceutical Company Limited held
256,657,251 voting securities (86.69% of the total number of voting
rights); and
-
Takeda Pharmaceuticals International AG held
11,651,778 voting securities (3.94% of the total number of voting
rights);
subtotal: 268,309,029 voting rights (90.62% of the
total number of voting rights).
-
Grifols S.A. held 0 voting securities;
-
Gri-Cel S.A. held 0 voting securities, and
-
Grifols Worldwide Operations Ltd. held 0 voting
securities.
Chain of
controlled undertakings through which the holdings are effectively
held: 1. Takeda Pharmaceuticals International AG is controlled
by Takeda Pharma A/S, which is controlled by Takeda A/S, which is
controlled by Takeda Pharmaceutical Company Limited and by Takeda
Europe Holdings B.V., which is controlled by Takeda Pharmaceutical
Company Limited. 2. Gri-Cel, S.A. is controlled by Instituto
Grifols, S.A., which is controlled by Grifols, S.A. 3. Grifols
Worldwide Operations Ltd. is controlled by Grifols, S.A.
2. Content of the
notification of Bank of America Corporation
Date of the
notification: June 18, 2018.
Reason of the
notification: acquisition or disposal of financial instruments
that are treated as voting securities / downward crossing of the
lowest threshold.
Person subject to
the notification requirement: Bank of America Corporation (with
address at Wilmington, D.E., United States), who is a parent
undertaking/controlling person.
Date on which the
threshold was crossed: June 11, 2018.
Threshold that
was crossed: 3%.
Denominator:
296,067,856.
Details of the
notification: following the disposal of financial instruments
that are treated as voting securities, the number of voting rights
was as follows:
-
Bank of America Corporation held 0 voting
securities; and
-
Bank of America, National Association held 0
voting securities;
and the number of equivalent financial instruments
was as follows:
Chain of
controlled undertakings through which the holding is effectively
held: Merrill Lynch Professional Clearing Corporation and Bank
of America, National Association are controlled by Bank of America
Corporation. Bank of America Corporation is not a controlled
entity.
This press release and the above-mentioned
transparency notifications can be consulted on our website:
For more
information:
TiGenix
Claudia Jiménez
Senior Director Investor Relations and Communications
Tel: +34918049264
Claudia.jimenez@tigenix.com
About TiGenix
TiGenix NV
(Euronext Brussels and NASDAQ: TIG) is an advanced
biopharmaceutical company developing novel therapies for serious
medical conditions by exploiting the anti-inflammatory properties
of allogeneic, or donor-derived, stem cells.
TiGenix lead
product, Alofisel (darvadstrocel), previously Cx601, received
European Commission (EC) approval for the treatment of complex
perianal fistulas in adult patients with non-active/mildly active
luminal Crohn's disease, when fistulas have shown an inadequate
response to at least one conventional or biologic therapy. A global
Phase III trial intended to support a future U.S. Biologic License
Application (BLA) started in 2017. TiGenix has entered into a
licensing agreement with Takeda, a global pharmaceutical company
active in gastroenterology, under which Takeda acquired the
exclusive right to develop and commercialize Alofisel for complex
perianal fistulas outside the U.S. TiGenix' second adipose-derived
product, Cx611, is undergoing a Phase I/II trial in severe sepsis -
a major cause of mortality in the developed world. TiGenix is
headquartered in Leuven (Belgium) and has operations in Madrid
(Spain) and Cambridge, MA (USA). For more information, please visit
http://www.tigenix.com.
This
announcement is distributed by Nasdaq Corporate Solutions on behalf
of Nasdaq Corporate Solutions clients.
The issuer of this announcement warrants that they are solely
responsible for the content, accuracy and originality of the
information contained therein.
Source: TiGenix via Globenewswire
Trean Insurance (NASDAQ:TIG)
Historical Stock Chart
From Jun 2024 to Jul 2024
Trean Insurance (NASDAQ:TIG)
Historical Stock Chart
From Jul 2023 to Jul 2024